Sperm-associated antigen 17 (SPAG17)

About Sperm-associated antigen 17

Sperm-associated antigen 17 (SPAG17) is a protein from Homo sapiens identified by UniProt accession Q6Q759, 2223 residues long. MolForge cross-references it against 0 known binders and 195 disease associations.

Target properties

Protein name	Sperm-associated antigen 17
UniProt accession	Q6Q759
Gene	SPAG17
Organism	Homo sapiens
Length	2223 residues
Molecular weight	—
EC numbers	—
Target class	UNCLASSIFIED
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (195)

Diseases linked to this target (Open Targets).

spermatogenic failure 55 · score 0.55
body height · score 0.42
BMI-adjusted waist circumference · score 0.42
body mass index · score 0.39
smoking behavior · score 0.39
male infertility with azoospermia or oligozoospermia due to single gene mutation · score 0.38
BMI-adjusted waist-hip ratio · score 0.38
physical activity measurement · score 0.38
hair shape measurement · score 0.38
lean body mass · score 0.37

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q6Q759-F1	alphafold	PREDICTED	63.74	—

Amino-acid sequence (2223 residues)

MAPKKEKGGT VNTSSKIWEP SLIAAQFNQN DWQASIAFVV GNQIEDDLLI QALTVAVQVP QRKLFSMVSW QDILQQINEI NTLVGSASSK KAKKPVGGNA PLYYEVLTAA KAIMDSGEKL TLPLIGKLLK FQLLQIKFKD QQRRENEKKV IEDKPKLEKD KGKAKSPKEK KAPSAKPAKG KGKDQPEANA PVKKTTQLKR RGEDDHTNRY IDDEPDDGAQ HYIIVVGFNN PQLLAIMAEL GIPITSVIKI SSENYEPLQT HLAAVNQQQE VLLQSEDLEA EKLKKENAIK ELKTFWKYLE PVLNNEKPET NLFDVARLEY MVKAADFPSD WSDGEMMLKL GTDIFENIAC LMYDILDWKR QHQHYLESMQ LINVPQVVNE KPVLEAMPTS EAPQPAVPAP GKKKAQYEEP QAPPPVTSVI TTEVDMRYYN YLLNPIREEF ISVPLILHCM LEQVVATEED LVPPSLREPS PRADGLDHRI AAHIVSLLPS LCLSEREKKN LHDIFLSEEE NESKAVPKGP LLLNYHDAHA HKKYALQDQK NFDPVQIEQE MQSKLPLWEF LQFPLPPPWN NTKRLATIHE LMHFCTSDVL SWNEVERAFK VFTFESLKLS EVDEKGKLKP SGMMCGSDSE MFNIPWDNPA RFAKQIRQQY VMKMNTQEAK QKADIKIKDR TLFVDQNLSM SVQDNESNRE PSDPSQCDAN NMKHSDLNNL KLSVPDNRQL LEQESIMKAQ PQHESLEQTT NNEIKDDAVT KADSHEKKPK KMMVEADLED IKKTQQRSLM DWSFTEHFKP KVLLQVLQEA HKQYRCVDSY YHTQDNSLLL VFHNPMNRQR LHCEYWNIAL HSNVGFRNYL ELVAKSIQDW ITKEEAIYQE SKMNEKIIRT RAELELKSSA NAKLTSASKI FSIKESKSNK GISKTEISDQ EKEKEKEKIP FILEGSLKAW KEEQHRLAEE ERLREEKKAE KKGKEAGKKK GKDNAEKEDS RSLKKKSPYK EKSKEEQVKI QEVTEESPHQ PEPKITYPFH GYNMGNIPTQ ISGSNYYLYP SDGGQIEVEK TMFEKGPTFI KVRVVKDNHN FMIHLNDPKE IVKKEEKGDY YLEEEEEGDE EQSLETEVSD AKNKAFSKFG SFSATLENGI CLSISYYGSN GMAPEDKDPD LETILNIPSA LTPTVVPVIV TVPQSKAKGK IKGKEKPKES LKEEEHPKEE EKKEEEVEPE PVLQETLDVP TFQSLNVSCP SGLLLTFIGQ ESTGQYVIDE EPTWDIMVRQ SYPQRVKHYE FYKTVMPPAE QEASRVITSQ GTVVKYMLDG STQILFADGA VSRSPNSGLI CPPSEMPATP HSGDLMDSIS QQKSETIPSE ITNTKKGKSH KSQSSMAHKG EIHDPPPEAV QTVTPVEVHI GTWFTTTPEG NRIGTKGLER IADLTPLLSF QATDPVNGTV MTTREDKVVI VERKDGTRIV DHADGTRITT FYQVYEDQII LPDDQETTEG PRTVTRQVKC MRVESSRYAT VIANCEDSSC CATFGDGTTI IAKPQGTYQV LPPNTGSLYI DKDCSAVYCH ESSSNIYYPF QKREQLRAGR YIMRHTSEVI CEVLDPEGNT FQVMADGSIS TILPEKKLED DLNEKTEGYD SLSSMHLEKN HQQIYGEHVP RFFVMYADGS GMELLRDSDI EEYLSLAYKE SNTVVLQEPV QEQPGTLTIT VLRPFHEASP WQVKKEDTIV PPNLRSRSWE TFPSVEKKTP GPPFGTQIWK GLCIESKQLV SAPGAILKSP SVLQMRQFIQ HEVIKNEVKL RLQVSLKDYI NYILKKEDEL QEMMVKDSRT EEERGNAADL LKLVMSFPKM EETTKSHVTE VAAHLTDLFK QSLATPPKCP PDTFGKDFFE KTWRHTASSK RWKEKIDKTR KEIETTQNYL MDIKNRIIPP FFKSELNQLY QSQYNHLDSL SKKLPSFTKK NEDANETAVQ DTSDLNLDFK PHKVSEQKSS SVPSLPKPEI SADKKDFTAQ NQTENLTKSP EEAESYEPVK IPTQSLLQDV AGQTRKEKVK LPHYLLSSKP KSQPLAKVQD SVGGKVNTSS VASAAINNAK SSLFGFHLLP SSVKFGVLKE GHTYATVVKL KNVGVDFCRF KVKQPPPSTG LKVTYKPGPV AAGMQTELNI ELFATAVGED GAKGSAHISH NIEIMTEHEV LFLPVEATVL TSSNYDKRPK DFPQGKENPM VQRTSTIYSS TLGVFMSRKV SPH

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards